PHARMALGEN YELLOW HORNET VENOM 1.1 MG
DOLICHOVESPULA ARENARIA VENOM PROTEIN EXTRACT : 1.1 MG · DIN 01948938 · ALK-ABELLO A/S
Health Canada status: CANCELLED POST MARKET
What is PHARMALGEN YELLOW HORNET VENOM?
PHARMALGEN YELLOW HORNET VENOM 1.1 MG contains DOLICHOVESPULA ARENARIA VENOM PROTEIN EXTRACT : 1.1 MG. It is listed in the Health Canada Drug Product Database under DIN 01948938, held by ALK-ABELLO A/S, supplied as POWDER FOR SOLUTION for SUBCUTANEOUS ; INTRADERMAL administration. Health Canada currently lists it as cancelled post market, status dated 07-Feb-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PHARMALGEN YELLOW HORNET VENOM used for?
Diagnosis and treatment of Hymenoptera (Honey Bee, Yellow Jacket, Yellow Hornet, White Faced Hornet, Wasp, Mixed Vespid) sting allergy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01948938 |
|---|---|
| Brand name | PHARMALGEN YELLOW HORNET VENOM |
| Generic / active ingredient | DOLICHOVESPULA ARENARIA VENOM PROTEIN EXTRACT : 1.1 MG |
| Manufacturer | ALK-ABELLO A/S |
| Strength | 1.1 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRADERMAL |
| Schedule | Schedule D |
| ATC code | V01AA07 INSECTS |
| AHFS class | 92:05.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 07-Feb-2023 |
| Original market date | 1996-09-16 00:00:00 |
How is it administered?
Subcutaneous injection. Build-up phase followed by maintenance (typically 100 mcg). Dose must be adjusted based on patient sensitivity and tolerance of previous doses.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted solutions should be discarded after four hours to avoid contamination. (Note: specific temperature for powder not in provided text).
How is it supplied?
Vials of freeze-dried extract; diagnostic kits containing five individual venom extracts.
Contraindications
Immune pathologic conditions, malignancy, unstable/severe asthma, chronic heart/lung disease, treatment with beta-blockers, ACE inhibitors, tricyclic antidepressants, or MAOIs.
Warnings and precautions
Risk of fatal anaphylaxis. Administer only under medical supervision with resuscitation equipment. Observe patient for 30+ mins. Avoid intravascular injection.
What can be used instead?
Other Canadian products sharing ATC code V01AA07 INSECTS. 5 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HYMENOPTERA VENOM PRODUCT - HONEY BEE VENOM (550 MCG) | 550 MCG | POWDER FOR SOLUTION | JUBILANT HOLLISTERSTIER LLC | MARKETED | DIN 02220075 |
| HYMENOPTERA VENOM PRODUCT - YELLOW JACKET VENOM PROTEIN (550 MCG) | 550 MCG | POWDER FOR SOLUTION | JUBILANT HOLLISTERSTIER LLC | MARKETED | DIN 02220113 |
| HYMENOPTERA VENOM PRODUCT-MIXED VESPID VENOM PROTEIN (1650 MCG) | 550 MCG | POWDER FOR SOLUTION | JUBILANT HOLLISTERSTIER LLC | MARKETED | DIN 02221314 |
| HYMENOPTERA VENOM PRODUCT-WASP VENOM PROTEIN (550 MCG) | 550 MCG | POWDER FOR SOLUTION | JUBILANT HOLLISTERSTIER LLC | MARKETED | DIN 02220091 |
| HYMENOPTERA VENOM PRODUCTS-YELLOW HORNET VENOM PROTEIN (550 MCG) | 550 MCG | POWDER FOR SOLUTION | JUBILANT HOLLISTERSTIER LLC | MARKETED | DIN 02220083 |
| HONEY BEE VENOM INJ | 500 MCG | POWDER FOR SOLUTION | HOLLISTER-STIER, UNIT PHARM, DIVISION OF MILES CANADA INC. | CANCELLED POST MARKET | DIN 00499676 |
| HONEY BEE VENOM MULTIDOSE 13.0 ML (1300MCG) | 1300 MCG | POWDER FOR SOLUTION | JUBILANT HOLLISTERSTIER LLC | DORMANT | DIN 02230860 |
| HYMENOPTERA VENOM PRODUCT-WHITE-FACED HORNET VENOM PROTEIN (550 MCG) | 550 MCG | POWDER FOR SOLUTION | JUBILANT HOLLISTERSTIER LLC | DORMANT | DIN 02220105 |
| MIXED VESPID VENOM PROTEIN INJ | 550 MCG | POWDER FOR SOLUTION | HOLLISTER-STIER, UNIT PHARM, DIVISION OF MILES CANADA INC. | CANCELLED POST MARKET | DIN 00583448 |
| MIXED VESPID VENOM PROTEIN MULTIDOSE 13.0 ML (3900 MCG) | 1300 MCG | POWDER FOR SOLUTION | JUBILANT HOLLISTERSTIER LLC | DORMANT | DIN 02230862 |
Who else supplies INSECTS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INSECTS appears in 10 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.